Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.5% – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 5.5% during mid-day trading on Tuesday . The stock traded as low as $23.45 and last traded at $23.01. Approximately 14,342 shares traded hands during trading, a decline of 94% from the average daily volume of 224,916 shares. The stock had previously closed at $24.34.

Analyst Upgrades and Downgrades

Several brokerages have commented on DNTH. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. Oppenheimer raised their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $46.83.

Dianthus Therapeutics Trading Down 4.6 %

The firm has a market capitalization of $687.09 million, a PE ratio of -9.24 and a beta of 1.82. The firm’s fifty day moving average price is $22.56 and its 200 day moving average price is $25.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC raised its stake in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares during the period. MetLife Investment Management LLC boosted its holdings in Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after purchasing an additional 7,854 shares during the period. Walleye Capital LLC bought a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $821,000. Finally, Braidwell LP raised its position in shares of Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after buying an additional 126,836 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.